NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Qing Li Peptide

Published 12 Nov 2026. 39-page investigative report on who is behind Qing Li Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 368 Finnrick lab tests, Qing Li Peptide’s overall pass rate is 65%: 239 pass and 128 fail. The record is uneven rather than uniformly good or bad. GHK-Cu and Tirzepatide sit at the strong end, while TB-500 and Tesamorelin define the weak tail. Stricter Finnrick grading contracts some ratings, especially around the middle of the catalogue.

The quality record now sits behind a closure notice. The canonical site says Qing Li Peptide ceased operations on 2026-10-01 and warns that entities claiming representation are fraudulent; shop, checkout and product paths redirect to the closed homepage. Dated buyer reports allege September orders, silent reps, labels without carrier movement and uneven refund anecdotes, while crypto and transfer rails limit recourse.

The investigation follows the identity trail behind that shutdown. Domain and archive records conflict with 7-year, 2012–2026 and 20+ year marketing history claims, and the public pages did not identify a contracting legal person. Hong Kong filings verify Bestbell, Fengyun and Weili, but not an ownership chain to Qing Li. The stronger cluster evidence is commercial: shared Stella and staff imagery, Peptides Factory/Bestbell/Fengyun traces, TingPeptide and DDG Weili claims, and Norco content carrying Qing Li language forward.

Qing Li is not a current purchasing option. The report is most useful for existing stock, successor or copycat claims, and deciding which related brands need extra verification before money moves.

Inside the full report:

  • Appendix A with per-product pass/fail rates, methodology-divergence charts and rating trajectories for all 15 tested products
  • Closure exhibits: homepage modal, storefront redirects, Wayback capture and stale social surfaces
  • Hong Kong registry extracts for Bestbell, Fengyun and Weili with ownership-chain limits
  • Personnel-asset comparison linking Qing Li and Peptides Factory through shared staff imagery
  • Related-storefront cluster analysis covering Peptides Factory, TingPeptide, DDG, Norco, Weitai, BB-Pep and Pioneer watch items
  • Payment/refund analysis and dated buyer-report pattern for outstanding-order risk

Risk assessment

  • Product-specific quality risk — high: Fail-heavy Qing Li products include TB-500 26.36%, MOTS-c 33.59%, CJC-1295 35.27%, Tesamorelin 37.6% and BPC-157 43.3%; top products tested materially better but the storefront is closed.
  • Service-continuity and non-delivery risk — high: Qing Li’s site says operations ceased on 2026-10-01, commerce pages redirect and public reports describe September orders, silent reps and tracking labels without movement.
  • Payment-recourse and refund risk — high: Qing Li advertised crypto, T/T, Wise and Alibaba while refund wording centered on PayPal, and no post-closure claims channel, legal entity or administrator was published.
  • Legal-counterparty and history-claim risk — high: The public pages did not name the contracting entity, UBO was unresolved and 7+ year / 2012–2026 history claims conflict with the 2024 domain and 2025 staff-domain record.
  • Brand-confusion and successor/copycat risk — high: Qing Li warned that entities claiming representation are fraudulent, while stale socials, unresolved Facebook/Telegram channels, Norco clone content and related storefronts remain visible.
  • Manufacturing and COA-verification risk — medium: GMP, Janoshik and quality-control claims were not independently verified; no named QA or batch-release authority was established, and the January 2025 archive showed steroid/tablet/oil categories.